{
    "EVIDENCE": {
        "id": 405,
        "name": "EID405",
        "description": "A head-to-tail in-frame fusion between exon1 of DNAJB1 and exon2 of PRKACA resulting from a ~400kb deletion was observed in 100% (15/15) fibrolamellar hepatocellular carcinomas examined. The fusion was confirmed at both RNA and DNA level in all primary and metastatic tumor samples but not in adjacent normal tissue. Immunoprecipitation and Western blot analyses confirmed that the chimeric protein is expressed in tumor tissue, and a cell culture assay indicated that it retains kinase activity.",
        "disease": {
            "id": 44,
            "name": "Fibrolamellar Carcinoma",
            "display_name": "Fibrolamellar Carcinoma",
            "doid": "5015",
            "url": "http://www.disease-ontology.org/?id=DOID:5015"
        },
        "drugs": [],
        "rating": 4,
        "evidence_level": "B",
        "evidence_type": "Diagnostic",
        "clinical_significance": "Positive",
        "evidence_direction": "Supports",
        "variant_origin": "Somatic",
        "drug_interaction_type": null,
        "status": "accepted",
        "type": "evidence",
        "source": {
            "id": 22,
            "name": "Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.",
            "citation": "Honeyman et al., 2014, Science",
            "citation_id": "24578576",
            "source_type": "PubMed",
            "asco_abstract_id": null,
            "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24578576",
            "open_access": true,
            "pmc_id": "PMC4286414",
            "publication_date": {
                "year": 2014,
                "month": 2,
                "day": 28
            },
            "journal": "Science",
            "full_journal_title": "Science (New York, N.Y.)",
            "status": "fully curated",
            "is_review": false,
            "clinical_trials": []
        },
        "variant_id": 31,
        "phenotypes": [],
        "assertions": [
            {
                "id": 24,
                "type": "assertion",
                "name": "AID24",
                "summary": "DNAJB1-PRKACA fusion is highly sensitive and specific for diagnosis of fibrolamellar hepatocellular carcinoma",
                "description": "A head-to-tail in-frame fusion between exon1 of DNAJB1 and exon2 of PRKACA, resulting from a ~400kb genomic deletion, has been reported has highly recurrent in fibrolamellar HCC. Detection of this fusion by RNAseq, RT-PCR and FISH has subsequently shown this fusion to be highly sensitive and specific for diagnosis of fibrolamellar HCC and mixed fibrolamellar HCC. Several hundred fibrolamellar HCC, non-FL HCC or non-malignant tissues have now been assayed to demonstrate this.",
                "gene": {
                    "name": "PRKACA",
                    "id": 17
                },
                "variant": {
                    "name": "DNAJB1-PRKACA",
                    "id": 31
                },
                "disease": {
                    "id": 44,
                    "name": "Fibrolamellar Carcinoma",
                    "display_name": "Fibrolamellar Carcinoma",
                    "doid": "5015",
                    "url": "http://www.disease-ontology.org/?id=DOID:5015"
                },
                "drugs": [],
                "evidence_type": "Diagnostic",
                "evidence_direction": "Supports",
                "clinical_significance": "Positive",
                "fda_regulatory_approval": false,
                "status": "accepted"
            }
        ],
        "gene_id": 17
    },
    "GENE": {
        "id": 17,
        "name": "PRKACA",
        "entrez_id": 5566,
        "description": "PRKACA has been studied in breast cancer and has been found to mediate resistance to HER2 targeted therapies. It has also been found to contain a mutation hotspot that contributes to neoplastic behavior in neuroendocrine cancers. In hepatocellular fibrolamellar carcinoma (FL-HCC), the fusion DNAJB1 to PRKACA is suggested to be a diagnostic marker for this rare subtype of HCC. In one study, this fusion was observed in 15/15 FL-HCC cases examined and functional studies found that the fusion retained kinase activity.",
        "variants": [
            {
                "name": "DNAJB1-PRKACA",
                "id": 31,
                "evidence_items": {
                    "accepted_count": 4,
                    "rejected_count": 0,
                    "submitted_count": 0
                }
            }
        ],
        "aliases": [
            "CAFD1",
            "PRKACA",
            "PPNAD4",
            "PKACA"
        ],
        "type": "gene"
    },
    "VARIANT": {
        "id": 31,
        "entrez_name": "PRKACA",
        "entrez_id": 5566,
        "name": "DNAJB1-PRKACA",
        "description": "This fusion has been found to be very recurrent in the rare form of adolescent liver cancer, fibrolamellar hepatocellular carcinoma. In one study, this fusion was observed in 15/15 FL-HCC cases examined and functional studies found that the fusion retained kinase activity. The presence of this fusion may be used as a diagnostic marker for this rare tumor type.",
        "gene_id": 17,
        "type": "variant",
        "variant_types": [
            {
                "id": 120,
                "name": "transcript_fusion",
                "display_name": "Transcript Fusion",
                "so_id": "SO:0001886",
                "description": "A feature fusion where the deletion brings together transcript regions.",
                "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001886"
            }
        ],
        "civic_actionability_score": 75,
        "coordinates": {
            "chromosome": "19",
            "start": 14628951,
            "stop": 14629232,
            "reference_bases": null,
            "variant_bases": null,
            "representative_transcript": "ENST00000254322.2",
            "chromosome2": "19",
            "start2": 14202500,
            "stop2": 14218221,
            "representative_transcript2": "ENST00000308677.4",
            "ensembl_version": 75,
            "reference_build": "GRCh37"
        },
        "evidence_items": [
            {
                "id": 754,
                "name": "EID754",
                "description": "The DNAJB1-PRKACA fusion was detected in 79% (58/73) of fibrolamellar hepatocellular carcinomas assayed.",
                "disease": {
                    "id": 44,
                    "name": "Fibrolamellar Carcinoma",
                    "display_name": "Fibrolamellar Carcinoma",
                    "doid": "5015",
                    "url": "http://www.disease-ontology.org/?id=DOID:5015"
                },
                "drugs": [],
                "rating": 4,
                "evidence_level": "B",
                "evidence_type": "Diagnostic",
                "clinical_significance": "Positive",
                "evidence_direction": "Supports",
                "variant_origin": "Somatic",
                "drug_interaction_type": null,
                "status": "accepted",
                "type": "evidence",
                "source": {
                    "id": 499,
                    "name": "Unique genomic profile of fibrolamellar hepatocellular carcinoma.",
                    "citation": "Cornella et al., 2015, Gastroenterology",
                    "citation_id": "25557953",
                    "source_type": "PubMed",
                    "asco_abstract_id": null,
                    "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/25557953",
                    "open_access": true,
                    "pmc_id": "PMC4521774",
                    "publication_date": {
                        "year": 2015,
                        "month": 4
                    },
                    "journal": "Gastroenterology",
                    "full_journal_title": "Gastroenterology",
                    "status": "fully curated",
                    "is_review": false,
                    "clinical_trials": []
                },
                "variant_id": 31,
                "phenotypes": []
            },
            {
                "id": 405,
                "name": "EID405",
                "description": "A head-to-tail in-frame fusion between exon1 of DNAJB1 and exon2 of PRKACA resulting from a ~400kb deletion was observed in 100% (15/15) fibrolamellar hepatocellular carcinomas examined. The fusion was confirmed at both RNA and DNA level in all primary and metastatic tumor samples but not in adjacent normal tissue. Immunoprecipitation and Western blot analyses confirmed that the chimeric protein is expressed in tumor tissue, and a cell culture assay indicated that it retains kinase activity.",
                "disease": {
                    "id": 44,
                    "name": "Fibrolamellar Carcinoma",
                    "display_name": "Fibrolamellar Carcinoma",
                    "doid": "5015",
                    "url": "http://www.disease-ontology.org/?id=DOID:5015"
                },
                "drugs": [],
                "rating": 4,
                "evidence_level": "B",
                "evidence_type": "Diagnostic",
                "clinical_significance": "Positive",
                "evidence_direction": "Supports",
                "variant_origin": "Somatic",
                "drug_interaction_type": null,
                "status": "accepted",
                "type": "evidence",
                "source": {
                    "id": 22,
                    "name": "Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.",
                    "citation": "Honeyman et al., 2014, Science",
                    "citation_id": "24578576",
                    "source_type": "PubMed",
                    "asco_abstract_id": null,
                    "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24578576",
                    "open_access": true,
                    "pmc_id": "PMC4286414",
                    "publication_date": {
                        "year": 2014,
                        "month": 2,
                        "day": 28
                    },
                    "journal": "Science",
                    "full_journal_title": "Science (New York, N.Y.)",
                    "status": "fully curated",
                    "is_review": false,
                    "clinical_trials": []
                },
                "variant_id": 31,
                "phenotypes": []
            },
            {
                "id": 532,
                "name": "EID532",
                "description": "RT-PCR and FISH assays were developed for the detection of rearrangements of the PRKACA locus. A total of 106 primary liver tumors were studied by RT-PCR (26 fibrolamellar carcinomas, 25 conventional hepatocellular carcinomas, 25 cholangiocarcinomas, 25 hepatic adenomas, and 5 hepatoblastomas). FISH was tested in 19 fibrolamellar carcinomas and in 6 scirrhous hepatocellular carcinomas. Evidence of the DNAJB1-PRKACA fusion was found in all fibrolamellar cases but not in other tumor types for both methods indicating that detection of DNAJB1-PRKACA is a very sensitive and specific finding in support of the diagnosis of fibrolamellar carcinoma.",
                "disease": {
                    "id": 44,
                    "name": "Fibrolamellar Carcinoma",
                    "display_name": "Fibrolamellar Carcinoma",
                    "doid": "5015",
                    "url": "http://www.disease-ontology.org/?id=DOID:5015"
                },
                "drugs": [],
                "rating": 5,
                "evidence_level": "B",
                "evidence_type": "Diagnostic",
                "clinical_significance": "Positive",
                "evidence_direction": "Supports",
                "variant_origin": "Somatic",
                "drug_interaction_type": null,
                "status": "accepted",
                "type": "evidence",
                "source": {
                    "id": 260,
                    "name": "DNAJB1-PRKACA is specific for fibrolamellar carcinoma.",
                    "citation": "Graham et al., 2015, Mod. Pathol.",
                    "citation_id": "25698061",
                    "source_type": "PubMed",
                    "asco_abstract_id": null,
                    "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/25698061",
                    "open_access": null,
                    "pmc_id": null,
                    "publication_date": {
                        "year": 2015,
                        "month": 6
                    },
                    "journal": "Mod. Pathol.",
                    "full_journal_title": "Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",
                    "status": "fully curated",
                    "is_review": false,
                    "clinical_trials": []
                },
                "variant_id": 31,
                "phenotypes": []
            },
            {
                "id": 1643,
                "name": "EID1643",
                "description": "A DNAJB1:PRKACA fusion transcript was detected at very high expression levels by RNA-Seq in a case of mixed fibrolamellar hepatocellular carcinoma. Subsequent analysis revealed the presence of this fusion in all primary and metastatic samples, including those with mixed or conventional HCC pathology. A second case of mFL-HCC confirmed that the fusion was detectable in conventional components. An expanded screen of 112 additional HCC samples and 44 adjacent non-tumor liver samples was positive for a third case of HCC with both conventional and fibrolamellar features but negative for all conventional HCC and adjacent non-tumor liver samples.",
                "disease": {
                    "id": 2961,
                    "name": "Mixed Fibrolamellar Hepatocellular Carcinoma",
                    "display_name": "Mixed Fibrolamellar Hepatocellular Carcinoma",
                    "doid": "0080182",
                    "url": "http://www.disease-ontology.org/?id=DOID:0080182"
                },
                "drugs": [],
                "rating": 4,
                "evidence_level": "C",
                "evidence_type": "Diagnostic",
                "clinical_significance": "Positive",
                "evidence_direction": "Supports",
                "variant_origin": "Somatic",
                "drug_interaction_type": null,
                "status": "accepted",
                "type": "evidence",
                "source": {
                    "id": 1089,
                    "name": "A genomic case study of mixed fibrolamellar hepatocellular carcinoma.",
                    "citation": "Griffith et al., 2016, Ann. Oncol.",
                    "citation_id": "27029710",
                    "source_type": "PubMed",
                    "asco_abstract_id": null,
                    "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27029710",
                    "open_access": true,
                    "pmc_id": "PMC4880064",
                    "publication_date": {
                        "year": 2016,
                        "month": 6
                    },
                    "journal": "Ann. Oncol.",
                    "full_journal_title": "Annals of oncology : official journal of the European Society for Medical Oncology",
                    "status": "fully curated",
                    "is_review": false,
                    "clinical_trials": []
                },
                "variant_id": 31,
                "phenotypes": []
            }
        ],
        "variant_groups": [],
        "assertions": [
            {
                "id": 24,
                "type": "assertion",
                "name": "AID24",
                "summary": "DNAJB1-PRKACA fusion is highly sensitive and specific for diagnosis of fibrolamellar hepatocellular carcinoma",
                "description": "A head-to-tail in-frame fusion between exon1 of DNAJB1 and exon2 of PRKACA, resulting from a ~400kb genomic deletion, has been reported has highly recurrent in fibrolamellar HCC. Detection of this fusion by RNAseq, RT-PCR and FISH has subsequently shown this fusion to be highly sensitive and specific for diagnosis of fibrolamellar HCC and mixed fibrolamellar HCC. Several hundred fibrolamellar HCC, non-FL HCC or non-malignant tissues have now been assayed to demonstrate this.",
                "gene": {
                    "name": "PRKACA",
                    "id": 17
                },
                "variant": {
                    "name": "DNAJB1-PRKACA",
                    "id": 31
                },
                "disease": {
                    "id": 44,
                    "name": "Fibrolamellar Carcinoma",
                    "display_name": "Fibrolamellar Carcinoma",
                    "doid": "5015",
                    "url": "http://www.disease-ontology.org/?id=DOID:5015"
                },
                "drugs": [],
                "evidence_type": "Diagnostic",
                "evidence_direction": "Supports",
                "clinical_significance": "Positive",
                "fda_regulatory_approval": false,
                "status": "accepted"
            }
        ],
        "variant_aliases": [],
        "hgvs_expressions": [],
        "clinvar_entries": [],
        "allele_registry_id": null
    },
    "ASSERTIONS": [
        {
            "id": 24,
            "type": "assertion",
            "name": "AID24",
            "summary": "DNAJB1-PRKACA fusion is highly sensitive and specific for diagnosis of fibrolamellar hepatocellular carcinoma",
            "description": "A head-to-tail in-frame fusion between exon1 of DNAJB1 and exon2 of PRKACA, resulting from a ~400kb genomic deletion, has been reported has highly recurrent in fibrolamellar HCC. Detection of this fusion by RNAseq, RT-PCR and FISH has subsequently shown this fusion to be highly sensitive and specific for diagnosis of fibrolamellar HCC and mixed fibrolamellar HCC. Several hundred fibrolamellar HCC, non-FL HCC or non-malignant tissues have now been assayed to demonstrate this.",
            "gene": {
                "name": "PRKACA",
                "id": 17
            },
            "variant": {
                "name": "DNAJB1-PRKACA",
                "id": 31
            },
            "disease": {
                "id": 44,
                "name": "Fibrolamellar Carcinoma",
                "display_name": "Fibrolamellar Carcinoma",
                "doid": "5015",
                "url": "http://www.disease-ontology.org/?id=DOID:5015"
            },
            "drugs": [],
            "evidence_type": "Diagnostic",
            "evidence_direction": "Supports",
            "clinical_significance": "Positive",
            "fda_regulatory_approval": false,
            "status": "accepted"
        }
    ]
}